| 王亚辉,王延滨,兀 尧,等.血清miR-17-5p对根治性前列腺切除术后前列腺癌挽救治疗结局的预测价值[J].肿瘤学杂志,2025,31(12):1077-1082. |
| 血清miR-17-5p对根治性前列腺切除术后前列腺癌挽救治疗结局的预测价值 |
| Predictive Value of Serum MiR-17-5p Levels for Salvage Treatment Outcomes in Prostate Cancer Patients After Radical Prostatectomy |
| 投稿时间：2024-09-26 |
| DOI：10.11735/j.issn.1671-170X.2025.12.B011 |
|
 |
| 中文关键词: miR-17-5p 前列腺肿瘤 淋巴结转移 挽救治疗 |
| 英文关键词:miR-17-5p prostate neoplasms lymph node metastasis salvage treatment |
| 基金项目:咸阳市秦都区科技计划项目（2022sf08） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘 要：［目的］ 探讨血清微小RNA-17-5p（microRNA-17-5p，miRNA-17-5p）对根治性前列腺切除术（radical prostatectomy，RP）后前列腺癌（prostate cancer，PCa）患者挽救治疗结局的预测价值。［方法］ 回顾性收集2015年1月至2022年9月期间在咸阳市第一人民医院接受RP和挽救治疗的94例PCa患者的临床资料，其中86例患者术后确诊为生化复发（biochemical recurrence，BCR），另8例患者术后前列腺特异性抗原（prostate-specific antigen，PSA）持续升高。应用实时荧光定量PCR法检测挽救治疗前血清miR-17-5p表达水平。［结果］ 挽救治疗后24例患者出现第2次BCR，37例患者发生临床进展，均纳入治疗失败组（n=61）。挽救治疗失败组患者血清miR-17-5p水平显著高于治疗成功组［1.98（1.23，2.97）vs 0.95（0.59，1.22）］，差异有统计学意义（P＜0.001）。血清miR-17-5p预测挽救治疗结局的受试者工作特征（receiver operating characteristic，ROC）曲线下面积为0.816，对应截断值为1.18，灵敏度和特异度分别为85.2%和75.8%。多因素回归分析显示血清miR-17-5p≥1.18（HR=2.918，95%CI：1.390~6.129，P=0.005）和淋巴结阳性数≥2（HR=2.269，95%CI：1.098~4.688，P=0.027）是挽救治疗失败的独立危险因素。血清miR-17-5p低表达（＜1.18）和高表达（≥1.18）患者的无进展生存率分别为73.53%、13.33%，中位无进展生存时间分别为25、20个月（χ2=15.023，P＜0.001）。［结论］ 血清miR-17-5p高表达与RP后伴/不伴淋巴结转移的PCa患者挽救治疗失败有关，血清miR-17-5p有望成为PCa预后预测生物标志物。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the predictive value of serum miRNA-17-5p levels in salvage treatment outcomes of prostate cancer (PCa) patients after radical prostatectomy. ［Methods］ Clinical data of 94 patients with PCa who received salvage treatment after radical prostatectomy in Xianyang First People’s Hospital from January 2015 to September 2022 were retrospectively analyzed， including 86 patients with biochemical recurrence (BCR) and 8 patients with increased prostate-specific antigen(PSA) after surgery. The expression levels of serum miR-17-5p were detected with qRT-PCR before salvage treatment. ［Results］ Treatment failure after salvage therapy was observed in 61 patients (treatment failure group)， including 24 cases with second BCR and 37 cases with clinical progression. The level of serum miR-17-5p in the treatment failure group was significantly higher than that in the treatment success group ［1.98 (1.23， 2.97) vs 0.95 (0.59， 1.22)， P<0.001］. The area under the receiver operating characteristic (ROC) curve of serum miR-17-5p level for predicting salvage treatment outcomes was 0.816， with cut-off value of 1.18 the sensitivity and specificity were 85.2% and 75.8%， respectively. Multivaraite regression analysis showed that serum miR-17-5p≥1.18 (HR=2.918， 95%CI： 1.390~6.129， P=0.005) and lymph node positivity≥2 (HR=2.269， 95%CI： 1.098~4.688， P=0.027) were independent risk factors for salvage treatment failure. The median progression-free survival (PFS) rate of patients with low miR-17-5p expression (＜1.18) and high expression(≥1.18) was 73.53% and 13.33%， respectively， and the PFS time was 25 and 20 months， respectively (χ2=15.023， P＜0.001). ［Conclusion］ The high expression of serum miR-17-5p is associated with the failure of salvage therapy in PCa patients with/without lymph node metastasis after radical prostatectomy， and serum miR-17-5p has the potential to become an effective prognostic biomarker for PCa. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |